Seroprevalence rate after one dose of varicella vaccine in infants

Journal of Infection

Volumn 61, Issue 1, 2010, Pages 66-72

  Kim, So Hee ^a   Lee, Hoan Jong ^a   Park, Su Eun ^b   Oh, Sung Hee ^c   Lee, Seong Yeon ^d   Choi, Eun Hwa ^a,d  

^a Seoul National University College of Medicine   (South Korea)

^b Pusan National University School of Medicine   (South Korea)

^c Hanyang University   (South Korea)

^d Seoul National University Bundang Hospital   (South Korea)

Author keywords

Fluorescent antibody to membrane antigen; Seroprevalence; Varicella vaccine

Indexed keywords

CHICKENPOX VACCINE; HERPES ZOSTER IMMUNOGLOBULIN; SUDUVAX; UNCLASSIFIED DRUG; VARI L; VARILIX;

ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; CHICKENPOX; CHILD; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENCE; FLUORESCENT ANTIBODY TO MEMBRANE ANTIGEN ASSAY; HUMAN; IMMUNOASSAY; INFANT; KOREA; MAJOR CLINICAL STUDY; MALE; MASS IMMUNIZATION; MEDICAL HISTORY; PRESCHOOL CHILD; SEROPREVALENCE; ADULT; IMMUNOLOGY; PROCEDURES; SOUTH KOREA;

ADULT; CHICKENPOX; CHICKENPOX VACCINE; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNOASSAY; INFANT; MALE; REPUBLIC OF KOREA; SEROEPIDEMIOLOGIC STUDIES;

EID: 77953810141     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jinf.2010.04.001     Document Type: Article

References (38)

1. Centers for Disease Control and Prevention Prevention of varicella. Recommendations of the Advisory Committee on immunization Practices (ACIP). MMWR 2007, 56(RR-4):1-40.
2. Takahashi M., Otsuka T., Okuno Y., Asano Y., Yazaki T., Isomura S. Live vaccine used to prevent the spread of varicella in children in hospital. Lancet 1974, 2:1288-1290.
3. World Health Organization (WHO) Immunization, vaccines and biologicals:varicella vaccines 2003, WHO, Geneva, Available at, [Accessed November 2007]. http://www.who.int/vaccines/en/varicella.shtml.
4. Sadzot-Delvaux C., Rentier B., Wutzler P., Asano Y., Suga S., Yoshikawa T., et al. Varicella vaccination in Japan, South Korea, and Europe. J Infect Dis 2008, 197(suppl 2):S185-S190.
5. Macartney K.K., Burgess M.A. Varicella vaccination in Australia and New Zealand. J Infect Dis 2008, 197(suppl 2):S191-S195.
6. Centers for Disease Control and Prevention Prevention of varicella. Recommendations of the Advisory Committee on immunization Practices (ACIP). MMWR 1996, 45(RR-11):1-36.
7. Lee HG, Lee HJ, Kim SH, Chun BC, Kim KH, Lee HJ. Immunization rate of the Korean children under 6 years or younger. Program and abstract, the 57th Annual Fall Meeting of the Korean Pediatric Society; Abstract No. Inf-O-16, p90, Seoul, Korea, October 19-20; 2007.
8. Choi E.H. Varicella vaccination: worldwide status and provisional updated recommendation in Korea. Korean J Pediatr Infect Dis 2008, 15:12-19.
9. Gershon A., Takahashi M., Seward J. Varicella vaccine. Vaccines 2004, 783-823. Saunders, Philadelphia. 4th ed. S. Plotkin, W. Orenstein (Eds.).
10. Williams V., Gershon A., Brunell P.A. Serologic response to varicella-zoster membrane antigens measured by direct immunofluorescence. J Infect Dis 1974, 130:669-672.
11. Michalik D.E., Steinberg S.P., Larussa P.S., Edwards K.M., Wright P.F., Arvin A.M., et al. Primary vaccine failure after 1 dose of varicella vaccine in healthy children. J Infect Dis 2008, 197:944-949.
12. Seward J.F., Watson B.M., Peterson C.L., Mascola L., Pelosi J.W., Zhang J.X., et al. Varicella disease after introduction of varicella vaccine in the United States, 1995-2000. JAMA 2002, 287:606-611.
13. Marin M., Meissner H.C., Seward J.F. Varicella prevention in the United States: a review of successes and challenges. Pediatrics 2008, 122:e744-e751.
14. Davis M.M., Patel M.S., Gebremariam A. Decline in varicella related hospitalizations and expenditures for children and adults after introduction of varicella vaccine in the United States. Pediatrics 2004, 114:786-792.
15. Nguyen H.Q., Jumaan A.O., Seward J.F. Decline in mortality due to varicella after implementation of varicella vaccination in the United States. N Engl J Med 2005, 352:450-458.
16. Zhou F., Harpaz R., Jumaan A.O., Winston C.A., Shefer A. Impact of varicella vaccination on health care utilization. JAMA 2005, 294:797-802.
17. Chaves S.S., Gargiullo P., Zhang J.X., Civen R., Guris D., Mascola L., et al. Loss of vaccine-induced immunity to varicella over time. N Engl J Med 2007, 356:1121-1129.
18. Vazquez M., LaRussa P.S., Gershon A.A., Steinberg S.P., Freudigman K., Shapiro E.D. The effectiveness of the varicella vaccine in clinical practice. N Engl J Med 2001, 344:955-960.
19. Vázquez M., LaRussa P.S., Gershon A.A., Niccolai L.M., Muehlenbein C.E., Steinberg S.P., et al. Effectiveness over time of varicella vaccine. JAMA 2004, 291:851-855.
20. Cohen J.I., Straus S.E., Arvin A.M. Varicella-zotster virus replication, pathogenesis, and management. Fields' virology 2007, 2773-2818. LWW, Philadelphia. 5th ed. D.M. Knipe, P.M. Howley (Eds.).
21. Storlie J., Maresova L., Jackson W., Grose C. Comparative analyses of the 9 glycoprotein genes found in wild-type and vaccine strains of varicella-zoster virus. J Infect Dis 2008, 197(suppl 2):S49-S53.
22. Steinberg S.P., Gershon A.A. Measurement of antibodies to varicella-zoster virus by using a latex agglutination test. J Clin Microbiol 1991, 29:1527-1529.
23. Larussa P., Steinberg S., Waithe E., Hanna B., Holzman R. Comparison of five assays for antibody to varicella-zoster virus and the fluorescent-antibody-to-membrane-antigen test. J Clin Microbiol 1987, 25:2059-2062.
24. Gershon A.A., Larussa P., Steinberg S. Detection of antibodies to varicella-zoster virus using a latex agglutination assay. Clin Diagn Virol 1994, 2:271-277.
25. Krah D.L. Assays for antibodies to varicella zoster virus. Infect Dis Clin North Am 1996, 10:507-527.
26. Bogger-Goren S., Baba K., Hurley P., Yabuuchi H., Takahashi M., Ogra P.L. Antibody response to varicella-zoster virus after natural or vaccine-induced infection. J Infect Dis 1982, 146:260-265.
27. Provost P.J., Krah D.L., Kuter B.J., Morton D.H., Schofield T.L., Wasmuth E.H., et al. Antibody assays suitable for assessing immune responses to live varicella vaccine. Vaccine 1991, 9:111-116.
28. White C.J., Kuter B.J., Hildebrand C.S., Isganitis K.L., Matthews H., Miller W.J., et al. Varicella vaccine (VARIVAX) in healthy children and adolescents: results from clinical trials, 1987 to 1989. Pediatrics 1991, 87:604-610.
29. Lau Y.L., Vessey S.J., Chan I.S., Lee T.L., Huang L.M., Lee C.Y., et al. A comparison of safety, tolerability and immunogenicity of Oka/Merck varicella vaccine and VARILRIX in healthy children. Vaccine 2002, 20:2942-2949.
30. Krause P.R., Klinman D.M. Efficacy, immunogenicity, safety, and use of live attenuated chickenpox vaccine. J Pediatr 1995, 127:518-525.
31. Kuter B., Matthews H., Shinefield H., Black S., Dennehy P., Watson B., et al. Ten year follow-up of healthy children who received one or two injections of varicella vaccine. Pediatr Infect Dis J 2004, 23:132-137.
32. Li S., Chan I., Matthews H., Heyse J.F., Chan C.Y., Kuter B.J., et al. Inverse relationship between six week postvaccination varicella antibody response to vaccine and likelihood of long term breakthrough infection. Pediatr Infect Dis J 2002, 21:337-342.
33. Saiman L., LaRussa P., Steinberg S.P., Zhou J., Baron K., Whittier S., et al. Persistence of immunity to varicella-zoster virus after vaccination of healthcare workers. Infect Control Hosp Epidemiol 2001, 22:279-283.
34. Seward J.F., Marin M., Vázquez M. Varicella vaccine effectiveness in the US vaccination program: a review. J Infect Dis 2008, 197(suppl 2):S82-S89.
35. Watson B., Boardman C., Laufer D., Piercy S., Tustin N., Olaleye D., et al. Humoral and cell-mediated immune responses in healthy children after one or two doses of varicella vaccine. Clin Infect Dis 1995, 20:316-319.
36. Watson B., Rothstein E., Bernstein H., Arbeter A., Arvin A., Chartrand S., et al. Safety and cellular and humoral immune responses of a booster dose of varicella vaccine 6 years after primary immunization. J Infect Dis 1995, 172:217-219.
37. Kang J.H., Kim J.H., Suh B.K. The immunogenicity and safety study of 47 passaged Oka strain live attenuated varicella vaccine in healthy children. Korean J Pediatr Infect Dis 1997, 4:257-264.
38. Sohn Y.M., Park C.Y., Hwang K.K., Woo G.J., Park S.Y. Safety and immunogenicity of live attenuated varicella virus vaccine (MAV/06 strain). J Korean Pediatr Soc 1994, 37:1405-1413.